Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)

Otsuka

Status: Completed

Conditions: Depressive Disorder, Major

Study type: Observational

Funder types: Industry

Identifiers

NCT01284218

CN138-609

Details and patient eligibility

About

To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.

Enrollment: 23,514 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥1 fill for an augmentation therapy medication from Table 1 during the identification period of 01 January 2005 - 30 November 2008.
• 12 months of continuous enrollment with medical and pharmacy benefits each before the index date (pre-index period) and after the index date (post-index period).
• ≥1 medical claim with a primary International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis for MDD (296.2x, 296.3x, 311.xx) during the pre-index period.
• Age ≥18 years as of the year of the pre-index period.

Exclusion criteria

• No pharmacy claims for atypical antipsychotics, mood stabilizers, anxiolytics, anticonvulsants, or stimulants, during the pre-index period.
• No medical claims with primary or secondary diagnoses for non-MDD episodic mood disorders or schizophrenia during the pre-index or post-index periods.

Trial design

23,514 participants in 5 patient groups

Aripiprazole cohort

Other atypical cohort

Other antidepressant cohort

Mood stabilizer cohort

Stimulant cohort